Clostridioides difficile (C. diff) is the most common healthcare-associated infection, causing antibiotic-associated diarrhea that may lead to pseudomembranous colitis and even death. C. diff has an enormous impact on healthcare systems worldwide. An estimated 124,0001 cases of Clostridioides difficile infection (CDI) occur annually in Europe, costing the EU up to €3 billion per year.2
The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridioides difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.
The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.
1. European Centre for Disease Prevention and Control (ECDC). Clostridium difficile infections. ecdc.europa.eu/en/healthtopics/healthcare-associated_infections/clostridium-difficile-infections/pages/clostridium-difficile-infections.aspx. Accessed February 17, 2017.
2. C Diff Foundation. C. difficile lnfectlon CDI - European Clinician Consensus Report with Recommendations for lmproved Management of CDI. 2014. cdifffoundation.org/2014/11/24/c-difficile-infection-cdi-european-clinician-consensus-report-with-recommendations-for-improved-management-of-cdi. Accessed February 17, 2017.